Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06122389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

StatusRecruiting
PhasePhase 3
Started2024-02-05
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 8, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-01-06
Study Identification, Study Status, Eligibility v4
Eligibility criteria+1 characters
[...] der is not limited; Histologically confirmed T-cell lymphoma; ECOG physical status must be 0 or 1; Life expectancy ≥12 we [...] ically normal; Liver and kidney function is basically normal:; Blood coagulation function is basically normal; Female subj [...] gastrectomy or gastric banding that affects drug absorption.; The subject is taking a known medium or strong CYP inducer; [...]
2024-03-18
Study Status v3
Start dateestimated 2024-03→confirmed 2024-02-05
2024-03-13
Study Identification, Study Status, Study Description, Conditions, Outcome Measures, Eligibility v2
Start date2024-02→2024-03
Eligibility criteria-18 characters
[...] ents who have received ≥ first-line treatment, at least one first-lineprior treatment is adequate; Have not received histone deacetylas [...] days prior to the first dose of study drug administration; The activeActive phase of HBV or HCV infection is known; A history of immunodeficiency, including HIV seropositive, [...]
Primary endpoints1 entry, revised
Progression Free Survival (PFS) as assessed by IRC
2024-01-30
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start date2023-11→2024-02
Study sites0→1
2023-11-05
Original filing
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
Trial Details
NCT Number NCT06122389
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Enrollment 130 participants
Start Date 2024-02-05
Primary Completion 2026-05 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-08